La Farma

[Dion Worles]

PTBio Farma (Persero) is an Indonesian state-owned enterprise based in Bandung, West Java and the only local vaccine manufacturer in Indonesia,[2] which produces vaccines and sera to support immunization in Indonesia and other countries.[3] Bio Farma vaccine produced vaccines against measles, polio, hepatitis B, and pentavalent vaccine.[2] Bio Farma has supplied vaccines to multiple countries through UNICEF, PAHO and other organizations.[4] Since 2020, it also serves as the holding company for listed state-owned enterprises Kimia Farma and Indofarma.[5]

During the administration of J.P. van Limburg Stirum, Hendrik Tillema recommended to move the capital of Dutch East Indies to Bandung due to its natural conditions and hilly terrain, making it easier to defend. The idea was gradually accepted and began to be implemented by the Dutch colonial government in early 1920s after it was supported by Prof. J. Klopper, Rector of Technische Hogeschool te Bandoeng at the time. Government and private offices along with other agencies began moving to Bandung, including the foreign trade office, salvation army, government bodies and 's Lands Koepok Inrichting en het Instituut Pasteur, which stayed in Bandung until the present day.[6] The agency has experienced several changes in name and legal entity, which are as follows:[7]

BETHESDA, Md., Jan. 14, 2021 /PRNewswire/ -- Precision Medicine Group ("PMG") announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies. Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma's unique expertise to Precision's suite of end-to-end cell and gene therapy capabilities to support development and commercialization.

Led by executive leaders Anshul Mangal, John Khoury, and Tony Khoury, Project Farma has distinguished itself as a global leader in planning and implementing complex biomanufacturing strategies and facilities for clients that range from start-up biotechnology companies to global biopharmaceutical companies and academic medical centers. Project Farma has led more than a dozen manufacturing facility builds with capital investments greater than $1 billion (including some of the leading FDA-approved cell and gene therapy medicines).

Mark Clein, CEO of Precision Medicine Group, commented on the acquisition, "Since 2013, Precision has supported over 70% of the FDA- approved cell and gene therapies and is now even better positioned to support the hundreds of therapeutic new entrants coming to market. With our acquisition of Project Farma, Precision is the only life-science services company with true end-to-end capabilities in cell and gene therapy."

Project Farma will be part of Precision for Medicine, PMG's research and development services arm. Commenting on the acquisition, Precision for Medicine's president Chad Clark explains, "In today's highly competitive and scrutinized advanced therapies marketplace, ensuring a safe, scalable, and high-quality manufacturing capability can be the difference between success and failure. Project Farma are the experts at defining and developing the optimal manufacturing strategy and leading implementation of a customized solution. This essential capability is now expanded and leveraged by the comprehensive cell and gene therapy services available through Precision ADVANCE."

Anshul Mangal shared, "We are excited to join Precision's cell and gene therapy collective, leveraging interconnected services to accelerate the development, manufacturing, and commercialization of advanced therapies." Added Tony Khoury, "We realize Precision ADVANCE presents an unbelievable opportunity to further next generation medicines and to further Project Farma's and Precision's shared mission to positively impact as many patients and families as possible."

About Precision Medicine GroupFormed in 2012, Precision Medicine Group is a specialized services company supporting next generation approaches to drug development and commercialization. Precision provides an integrated infrastructure that supports pharmaceutical and life science companies as they develop new products in the age of precision medicine. The company is headquartered in Bethesda, Maryland with offices throughout North America and Europe. For more information, visit precisionmedicinegrp.com.

About Precision for MedicinePrecision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with over 2,100 people in 35 locations in the U.S., Canada, and Europe. For more information, visit PrecisionForMedicine.com.

About Project FarmaProject Farma is a consulting firm providing biomanufacturing strategy and execution. Project Farma's services include providing technical operations strategy such as pipeline evaluation and mobilization, make vs buy, and GMP infrastructure and startup. They also include strategy execution by managing capital projects, CDMO selection and management, tech transfers and facility builds and providing engineering services in automation, validation, quality, reliability and maintenance. Project Farma clients include startups, established life science corporations, advanced therapy organizations, universities, hospitals, government agencies, financial institutions, not-for-profits, and CROs/CMOs. For more information, visit projectfarma.com.

About Precision ADVANCE, the cell & gene therapy collectivePrecision ADVANCE is a focused collection of interconnected services and teams uniquely positioned to address the complexities of clinical, regulatory, manufacturing, and commercial needs to successfully bring a cell or gene therapy to market. For more information, visit precisionmedicinegrp.com/advance.

The MOU exemplifies a strong commitment to public health and innovation, and was signed by officials from Bio Farma, BD and witnessed by the Indonesian Minister of Health, Deputy Chief of Mission (Minister), Embassy of the Republic of Indonesia, and other company officials.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

In early 2020, a state-owned pharmaceutical holding company was established with Bio Farma as its parent company. The establishment of this holding company is aimed to strengthen self-reliance of the national pharmaceutical industry, and also to increase the availability of products supporting the pharmaceutical ecosystem. For more information refer to: www.biofarma.co.id

Merck (NYSE:MRK), known as MSD outside the United States and Canada,

today announced the formation of a new joint venture (JV) with Supera

Farma Laboratorios S.A., a Brazilian pharmaceutical company co-owned by

Cristlia and Eurofarma. The new JV will market, distribute and sell a

portfolio of innovative pharmaceutical and branded generic products from

Merck, Cristlia and Eurofarma solely in the Brazilian retail sector.

Merck, through a subsidiary, will own 51 percent of the JV, and

Cristlia and Eurofarma will collectively own 49. The venture will be

managed by a joint board and leadership team consisting of members of

senior management from the three companies. Establishment of the JV is

subject to satisfying certain agreed upon closing conditions but is

scheduled to be completed later in 2012.

Cristlia Labs (Cristlia Produtos Quimicos Farmaceuticos Ltda.), a

privately held Brazilian company founded in 1972, produces high quality

medicines to address medical needs. Primarily focused on specialty areas

such as psychiatry, anesthesia and pain relief, the company has become a

healthcare leader across Latin America. Today, in addition to covering

all territories within Brazil, Cristlia exports reach approximately 40

countries across Latin America, the Middle East, Asia and Africa.

The company is a strong supporter of the Brazilian scientific community

and a large number of universities within the country. The company also

develops social responsibility and sustainability programs in the areas

of education, the donation of medicines, and the offer of aid and

assistance to poor communities. For more information, please visit

3a8082e126